CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology® (CST) where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Successful Immunofluorescence: The Importance of Validation

Read More
All Posts

Part one of a four-part series on Immunofluorescence. Check out Experimental Controls, Fixation and Permeabilization, and Antibody Dilution and Incubation Conditions.


After months of hard work, your research has zeroed in on a hypothesis you can test with immunofluorescence (IF). But now you have to make a choice. How do you decide which antibody to use to get reliable IF results? How do you know if the images are accurately reporting the target's localization? We explore some considerations in this post.

The primary antibody is a critical component of an IF experiment, and its performance directly affects data quality. Detection of a specific band on a western blot (WB) is not sufficient to guarantee a chosen antibody will perform in IF. WB analysis subjects proteins to harsh reducing/denaturing conditions that alter protein structure, so an epitope recognized by an antibody approved for WB may be buried and/or inaccessible for IF, where proteins remain in their native state.

Validate Specificity to Avoid Misleading IF Results

The α-Synuclein protein is highly expressed in the brain and its dysfunction plays a role in neurodegenerative diseases, such as Parkinson’s disease. In healthy tissue, α-Synuclein is expected to be localized to presynaptic terminals where it associates with synaptic vesicles.

CST scientists compared α-Synuclein (D37A6) XP® Rabbit mAb #4179 side-by-side with another company’s α-Synuclein antibody, using each at the manufacturer’s recommended dilution. Both antibodies performed as expected in WB. In IF, punctate staining consistent with presynaptic localization of α-Synuclein was observed in midbrain sections for #4179, while the other company’s antibody showed a less punctate pattern, but critically misreported localization in nuclei or soma (arrows).IF_Brochure_pt1_validation_image_rpl_1200x600.jpg

A “clean” WB is not sufficient to ensure performance and reliability of an antibody in IF analysis. WB analysis of extracts from mouse and rat brain using α-Synuclein (D37A6) XP® Rabbit mAb #4179 or the other company’s antibody to α-Synuclein (left). Confocal IF analysis (right) of [mouse] lower midbrain and hippocampus sections using #4179 (upper row) or the other company’s antibody (lower row). Neuronal soma/ nuclei that are mis-labeled for α-Synuclein with the other company’s antibody are noted with white arrows.

This experiment illustrates the importance of application-specific validation. 

Check back in the coming weeks, we'll have posts discussing the design of controls for IF, considerations for fixation and permeabilization, and antibody incubation conditions. You can also follow the link below to download the Guide to Successful Immunofluorescence, a handy resource packed with tips and the 9-step Protocol for a successful immunofluorescence experiment.

Download the Guide

Additional Resources:

Related Posts

CST® Antibodies Validated on the Leica Microsystems Cell DIVE Multiplexed Imaging Solution

True innovation comes from collaboration–from bringing experts together to create techniques and tools th...
Alexandra Foley Mar 15, 2023

International Women’s Day: Hear from CST Women in STEM

Today is International Women's Day, a day that was established to celebrate the social, economic, cultura...
Alexandra Foley Mar 8, 2023

tRNA Modification by m7G MTase: Understanding its Role in Cancer and Developmental Disorders

Guest blogger Richard I. Gregory, PhD, is a professor at Harvard Medical School and Principal Investigato...